Literature DB >> 33543465

Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.

Maria Aurora Grimaudo1.   

Abstract

Up until now, surgery, radiation, and chemotherapy remain the conventional methods used in cancer treatment. However, these treatments are widely associated with severe side effects due to toxicity on normal cells. Consequently, there is an urgent need for novel therapeutic approaches that are able to effectively and selectively target tumor cells without any adverse effects on normal cells. Among the new approaches, cancer immunotherapy seems promising in the fight against tumors thanks to its prolonged efficacy and lower toxicity compared to the traditional treatments.Research studies suggested that both adjuvants and antigens are essential to induce optimal anti-tumor immunity. Among the different delivery strategies, nanotechnology offers several advantages for the design of cancer vaccines. Indeed, nanocarriers can protect the encapsulated antigens and/or adjuvant from enzymatic degradation, sustain and control the release for the entrapped cargo, and enhance the immune responses.Several studies reported that different physical characteristics of nanoparticles affect their uptake in cells and the potential to induce cellular responses. Among them, particle size and surface chemistry resulted the most influent.Clinical trials and recent research papers on the use of nanotechnology in cancer immunotherapy support the idea that this strategy could be successful as weapon against cancer in the near future.

Entities:  

Keywords:  Cancer immunotherapy; Cell membrane coated nanoparticles; Gold nanoparticles; Hydrogel nanoparticles; Immune checkpoint inhibitors; Inorganic nanoparticles; Liposomes; Micelles; Nanotechnology; Nanovaccines; Polymeric nanoparticles

Year:  2021        PMID: 33543465     DOI: 10.1007/978-3-030-58174-9_13

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  74 in total

1.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

Review 2.  Current adjuvants and new perspectives in vaccine formulation.

Authors:  Emanuele Montomoli; Simona Piccirella; Baharak Khadang; Elisa Mennitto; Roberto Camerini; Alfonso De Rosa
Journal:  Expert Rev Vaccines       Date:  2011-07       Impact factor: 5.217

Review 3.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

Review 4.  Nanovaccines and their mode of action.

Authors:  Mehfuz Zaman; Michael F Good; Istvan Toth
Journal:  Methods       Date:  2013-04-24       Impact factor: 3.608

Review 5.  Nanoparticle-based immunotherapy for cancer.

Authors:  Kun Shao; Santiswarup Singha; Xavier Clemente-Casares; Sue Tsai; Yang Yang; Pere Santamaria
Journal:  ACS Nano       Date:  2014-12-23       Impact factor: 15.881

Review 6.  Nanoparticles for dendritic cell-based immunotherapy.

Authors:  Tuan Hiep Tran; Thi Thu Phuong Tran; Hanh Thuy Nguyen; Cao Dai Phung; Jee-Heon Jeong; Martina H Stenzel; Sung Giu Jin; Chul Soon Yong; Duy Hieu Truong; Jong Oh Kim
Journal:  Int J Pharm       Date:  2018-03-16       Impact factor: 5.875

Review 7.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  The application of nanotechnology in immune checkpoint blockade for cancer treatment.

Authors:  Huan Deng; Zhiping Zhang
Journal:  J Control Release       Date:  2018-10-01       Impact factor: 9.776

Review 9.  Cancer immunotherapies, their safety and toxicity.

Authors:  Gheath Alatrash; Haroon Jakher; Patricia D Stafford; Elizabeth A Mittendorf
Journal:  Expert Opin Drug Saf       Date:  2013-05-14       Impact factor: 4.250

Review 10.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

View more
  1 in total

1.  Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling.

Authors:  Davide Ferrari; Stefania Gessi; Stefania Merighi; Manuela Nigro; Alessia Travagli; Jorge S Burns
Journal:  Front Cell Dev Biol       Date:  2022-05-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.